NovoPair: De novo peptide sequencing for tandem mass spectra pair

peer-reviewed · 2014 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · 2014

peer-reviewed · 2014 IEEE International Conference on Bioinformatics and Biomedicine (BIBM) · 2014. Yan Yan et al. With tandem mass spectrometry (MS/MS), spectra can be generated by various methods including…
Date 2014-11-01
Type peer-reviewed
Venue 2014 IEEE International Conference on Bioinformatics and Biomedicine (BIBM)
Publisher IEEE
Contribution algorithm
DOI 10.1109/bibm.2014.6999144
Citations (OpenAlex) 5

Abstract

With tandem mass spectrometry (MS/MS), spectra can be generated by various methods including collision-induced dissociation (CID), higher-energy collisional dissociation (HCD), electron capture dissociation (ECD) and electron transfer dissociation (ETD). At the same time, de novo sequencing using multiple spectra from the same peptide is becoming popular in proteomics studies. The focus of this work is using a pair of spectra from CID (or HCD) and ECD (or ETD) fragmentation because of the complementarity between them. We present a new de novo sequencing method for such paired spectra named NovoPair, and compare its performance to another successful method named pNovo+. NovoPair extends our previously proposed graph model to suit paired spectra, and considers different ion types in the two spectra to extract more information. The results show that NovoPair outperforms pNovo+ in terms of full length peptide sequencing accuracy on three pairs of experimental datasets, with the accuracy increasing up to 13.6% compared to pNovo+.

Authors

  1. Yan Yan · University of Saskatchewan, University of Western Ontario
  2. Anthony J. Kusalik · University of Saskatchewan
  3. Fang-Xiang Wu · University of Saskatchewan

Methods and tools

  • NovoPair: Extends the authors’ spectrum graph model to pairs of CID or HCD and ECD or ETD spectra of the same peptide, using the ion types of both to improve full-length de novo sequencing accuracy over pNovo+.

Seen in the charts

Back to the full map

Back to top